Singapore - English - HSA (Health Sciences Authority)

mundipharma pharmaceuticals pte. ltd. - naloxone 18.00mg eqv naloxone hydrochloride anhydrous; oxycodone 36.00mg eqv oxycodone hydrochloride anhydrous - tablet, film coated, extended release - 20.00 mg/tablet - naloxone 18.00mg eqv naloxone hydrochloride anhydrous 20 mg; oxycodone 36.00mg eqv oxycodone hydrochloride anhydrous 40 mg

Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - naloxone 2.25mg eqv naloxone hydrochloride anhydrous; oxycodone 4.50mg eqv oxycodone hydrochloride anhydrous - tablet, film coated, extended release - 2.50 mg/tablet - naloxone 2.25mg eqv naloxone hydrochloride anhydrous 2.5 mg; oxycodone 4.50mg eqv oxycodone hydrochloride anhydrous 5 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - naloxone hydrochloride dihydrate 5.45mg equivalent to naloxone hydrochloride anhydrous 5 mg; oxycodone hydrochloride 10mg;   - modified release tablet - 10/5mg - active: naloxone hydrochloride dihydrate 5.45mg equivalent to naloxone hydrochloride anhydrous 5 mg oxycodone hydrochloride 10mg   excipient: ethylcellulose lactose monohydrate magnesium stearate opadry white 85f18422 povidone purified talc   stearyl alcohol - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia. the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - naloxone hydrochloride dihydrate 10.9mg equivalent to naloxone hydrochloride anhydrous 10 mg; oxycodone hydrochloride 20mg;   - modified release tablet - 20/10mg - active: naloxone hydrochloride dihydrate 10.9mg equivalent to naloxone hydrochloride anhydrous 10 mg oxycodone hydrochloride 20mg   excipient: ethylcellulose lactose monohydrate magnesium stearate opadry pink 85f24151 povidone purified talc   stearyl alcohol - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia. the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - naloxone hydrochloride dihydrate 21.8mg equivalent to naloxone hydrochloride anhydrous 20 mg; oxycodone hydrochloride 40mg;   - modified release tablet - 40/20mg - active: naloxone hydrochloride dihydrate 21.8mg equivalent to naloxone hydrochloride anhydrous 20 mg oxycodone hydrochloride 40mg   excipient: ethylcellulose lactose monohydrate magnesium stearate opadry yellow 85f32109 povidone purified talc   stearyl alcohol - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia. the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - naloxone hydrochloride dihydrate 2.73mg equivalent to naloxone hydrochloride anhydrous 2.5 mg; oxycodone hydrochloride 5mg;   - modified release tablet - 5/2.5mg - active: naloxone hydrochloride dihydrate 2.73mg equivalent to naloxone hydrochloride anhydrous 2.5 mg oxycodone hydrochloride 5mg   excipient: ethylcellulose hyprolose lactose monohydrate magnesium stearate opadry blue 85f30569 purified talc   stearyl alcohol - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia. the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.